Tags : FDA’s


Genentech’s Venclexta (venetoclax) Receives FDA’s Accelerated Approval for Patients with

Shots: The accelerated approval is based on M14-358 (P-Ib) & M14-387 study (I/II) results assessing Venclexta (400mg qd) + azacitidine & decitabine & Venclexta (600mg qd) + LDAC (low-dose cytarabine) respectively in patients with 1L AML. or for those ineligible for intensive induction CT aged ≥60 yrs. M14-358 & M14-387 study results: Venclexta + azacitidine […]Read More